AtaiBeckley

Atai Beckley helps people with severe depression and anxiety. The company creates new medicines that help the brain heal. These treatments provide faster relief than traditional mental health drugs.

Treating the Brain Differently

• BPL-003: Intranasal spray for treatment-resistant depression; it uses a compound that acts on serotonin receptors in the brain to help patients who do not respond to standard antidepressants.
• VLS-01: Oral film applied to the cheek; designed to deliver medication without needing an intravenous (IV) drip or needles.
• EMP-01: Tablet designed for social anxiety disorder; uses a specific version of MDMA to reduce fear and increase emotional openness during social interactions.
• Drug Discovery: Research program focused on finding new medicines; seeks to help brain health without causing hallucinations or long recovery times.

Strategic Shifts and New Partners

• Completed a strategic combination with Beckley Psytech Limited in November 2025 to create a broader portfolio of mental health treatments.
• Changed corporate domicile from the Netherlands to the United States in December 2025 to become AtaiBeckley Inc.
• Partnered with the National Institute on Drug Abuse in August 2025 through a grant worth up to $11.4 million for new drug research.

What Makes Them Stand Out

The company focuses on neuroplasticity, which refers to the brain's ability to repair and rewire itself. These treatments are designed to be fast-acting so they fit easily into standard two-hour doctor appointments.

Tracking the Numbers

• Revenue reached $1.1 million in Q4 2025, improving from a negative position of $5,000 in Q4 2024.
• Net loss deepened to $544.8 million in Q4 2025, worsening from a $39 million loss the year before.
• Free cash flow reached negative $48.3 million in Q4 2025, worsening by 97.9% compared to Q4 2024.
• Market capitalization rose to $1.3 billion in Q4 2025, representing a 503.4% increase year-over-year.
• Total workforce included 54 full-time employees at the end of the 2025 reporting period.

The Bottom Line

Atai Beckley has evolved from a holding firm into a unified clinical-stage biotechnology company. Its recent move to the United States and expanded pipeline reflect a focused effort to scale mental health care.